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Abstract
Prostate cancer cells have an exquisite tropism for bone, which clinically
translates into the highest rate of bone metastases amongst male cancers.
Although in the latest years there has been an active development of new
"bone targeted" therapies, modern diagnostic techniques for bone metastases
still relies mostly on (99m)Tc bone scanning (BS) and plain X-ray. BS
dramatically lacks specificity and sensitivity. Recent publications using modern
imaging technologies have clearly pinpointed that BS grossly underestimates
the true prevalence of bone metastasis. In addition BS does not allow tumour
measurement and is, therefore, not appropriate to monitor response to therapy.
This might be extremely important in patients harbouring high-risk localized
disease that are eventually candidate for local therapy. Here we reviewed what
are the emerging imaging strategies that are likely to supplant BS and to what
extent they can be used in the clinic already.
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Prostate cancer cells have an exquisite tropism for bone, which clinically translates into the highest rate of bone metastases
amongst male cancers. Although in the latest years there has been an active development of new “bone targeted” therapies,
modern diagnostic techniques for bone metastases still relies mostly on 99mTc bone scanning (BS) and plain X-ray. BS dramatically
lacks specificity and sensitivity. Recent publications using modern imaging technologies have clearly pinpointed that BS grossly
underestimates the true prevalence of bone metastasis. In addition BS does not allow tumour measurement and is, therefore,
not appropriate to monitor response to therapy. This might be extremely important in patients harbouring high-risk localized
disease that are eventually candidate for local therapy. Here we reviewed what are the emerging imaging strategies that are likely to
supplant BS and to what extent they can be used in the clinic already.
1. Introduction
In men over the age of 50, prostate cancer (PCa) is the most
commonly diagnosed cancer and the second leading cause of
death by cancer [1].With the intense use of PSA testing, most
PCa are diagnosed at an early stage, and most are candidate
to intent-to-cure therapies such as radical prostatectomy,
external beam radiation therapy, or seeds implant. Initially
essentially intended for low- or intermediate-risk disease,
local therapies are now more often indicated in patients
with high-risk localized disease and locally advanced disease.
Indeed, hormone therapy has failed to demonstrate to
increase overall survival when it was not associated with a
local treatment [2]. In that high-risk population; however, it
is critical to precisely rule out the presence ofmetastases since
as for today it still represents the tipping point for excluding
local control.
PCa cells spreading out of the prostate show an exquisite
tropism for bone. In most patients, the initial seeding of
metastatic deposits occurs in the hematopoietic red marrow
of the axial skeleton leading to the formation of bone
metastases (BMs). BMs represent the initial and the main
metastatic site in about 80% of PCa patients, therefore, being
one of the most important prognostic factors [3, 4]. Skeletal
complications, most commonly designed as “skeletal-related
events (SREs),” account for most of the PCa’s morbidity
and mortality [5]. Replacement of hematopoietic tissues
in the bone marrow by PCa cells leads to anaemia while
abnormal tissue growing in the bone marrow can lead to
pain, fractures, and spinal cord compression. As for today,
despite the development of bone-targeted strategies, BMs are
still considered incurable [6].
The main phenotypic manifestations of PCa BMs are
their tropism to the axial skeleton (skull, vertebra, ribs and
collar bone, scapula, and proximal femur) and their most
often osteoblastic appearance, resulting from the stimulation
of osteoblasts [6]. BM, are often associated with increased
levels of serum markers of osteoblastic proliferation, such as
bone-specific alkaline phosphatase [7].
Interestingly, there has been no major evolution in the
diagnostic algorithm for BM in the recent years. Most
international guidelines still recognized 99mTc bone scintig-
raphy (BS) and plain X-ray radiography as the cornerstone
diagnostic techniques to detect and follow BM [8, 9].
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Most modern clinical trials still incorporate BS as a major
component to define time to progression, although it is
recognized as not appropriate to measure tumour response
and required serial examinations to define progression [10–
12]. There are, however, several technological developments
addressing this important diagnostic aspect. Here we will
review some of these developments.
2. Why and When Bone Imaging Is Required?
Early BM detection is critical in the management of patients
with high-risk PCa. Newly diagnosed patients with localized
disease and nometastases may benefit from radical treatment
with curative intent. In contrast, most guidelines recognize
that patients with BM should be kept away from local
therapy to avoid unnecessary side eﬀects and treated with
systemic therapy [9]. With modern PSA-based diagnostic
strategies, many patients are diagnosed while they are still
asymptomatic. In screening trials, BMs are detected at
diagnosis in less than 10% of the patients [13]. This means
that there is no need to perform an initial BS in every
new patient. PSA value and Gleason’s score at diagnostic
remain the strongest BM’s indicators. In a study conducted
on 60 patients with newly diagnosed PCa, Rana et al.
demonstrated that the positive predictive value of a PSA
>100 ng/mL was 100% [14]. Together with PSA, cT3−4 stage
and a Gleason score >7 are the other predictors of BM;
their positive predictive value being, respectively, 71.4% and
81% [14]. Based on this trial and others, the EAU guidelines
recommend that [. . .] a staging bone scan may be superfluous
if the serum PSA concentration is less than 20 ng/mL in
asymptomatic patients with well-, or moderately diﬀerentiated
tumours. In contrast, in patients with poorly diﬀerentiated
tumours and locally advanced disease, a staging bone scan
should be obtained irrespective of the serum PSA value [. . .]
[9]. Briganti et al. have developed a risk stratification tool to
select patients requiring initial imaging from a series of 853
consecutive patients [15]. Their classification and regression
tree (CART) stratifies patients into low risk (biopsy Gleason
≤7, cT1−3, and PSA <10 ng/mL), intermediate risk (biopsy
Gleason ≤7, cT2−3, and PSA >10 ng/mL), and high risk
(biopsy Gleason >7) conferring a risk of BM of 1.8%, 8.5%,
and 16.4%. Briganti’s regression tree shows higher sensitivity
(87.5%) compared to the EAU, AUA, and NCCN guidelines
[8, 9, 16].
Later in the course of the disease, BM detection may be
discussed in case of PSA recurrence after radical treatment
or when the tumour becomes resistant to castration (CRCP).
This information may be important to guide initiation of
hormone therapy, chemotherapy, or bone-targeted agents.
Gomez et al. have evaluated the use of BS in 153 patients
presenting with a PSA recurrence after radical prostatectomy.
This study demonstrated that it is unlikely to have a positive
BS in patients with a serum PSA of <7 ng/mL except in
case of skeletal symptoms [17]. Pound et al. have reviewed
a large series of radical prostatectomy performed at the
Johns Hopkins University and identified 304 patients with
a subsequent PSA rise [18]. The median actuarial time to
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Figure 1: Example of a 55 years old patient diagnosed with high-
risk localized disease. 99mTc bone scan shows an area of uptake in
the body of the 3rd lumbar vertebra ((a) and (b)). Confirmatory
X-ray is read as normal (c) although MRI of the axial skeleton (T1
sequence, (d)) shows a large focal area of malignant replacement of
the bone marrow.
metastases was 8 years from the time of PSA level elevation.
In survival analysis, time to biochemical progression ≤2
years (P < 0.001), Gleason’s score ≤8 (P < 0.001), and
PSA doubling time ≤10 months (PSADT) (P < 0.001) were
predictive of the probability and time to the development of
metastatic disease. Choueiri et al. have reviewed case notes
of 292 patients from CaPSURE who had recurrence and
had undergone at least 1 imaging study (BS, computerized
tomography (CT), or magnetic resonance imaging (MRI) of
the abdomen and the pelvis) [19]. Overall only 11% patients
showed a positive imaging study, and this was unlikely to
occur when PSA was≤5 ng/mL or PSADT≥10 months [19].
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Figure 2: Consecutive series of three 99mTc bone scans (BS) and MRI acquired three months apart on a patient included in a clinical trial
designed for M0 CRPC. Only the third BS is adjudicated as positive by the central review although he was already progressive on MRI at the
second metastatic workup.
Smith et al. have reported the natural history of 201 non-
metastatic (M0) CRCP patients consisting of the placebo
group of an aborted trial with zoledronic acid [20]. At 2
years, only 33% of patients had developed BM. A baseline
PSA level >10 ng/mL and a high PSA velocity independently
predicted shorter time to first BM. Patients with a PSADT
<6 months were those most likely to rapidly develop BM.
More recently, Smith et al. have reported the natural history
of placebo group of another M0 CRCP study conducted
with the endothelin receptor A inhibitor, atrasentan [21].
Patients included in the atrasentan trial had a shorter
PSADT (mean ± SD: 5.9 ± 3.62 months) than those in the
zoledronic acid trial (mean± SD: 9.7± 4.7 months) [20, 21].
In multivariate analyses, a baseline PSA ≥13.1 ng/mL was
associated with shorter time to the first BM and BM-free
survival.
In conclusion, all these data pinpoint at a high Gleason’s
score, a high PSA, and a short PSADT being important to
decide which patients should receive bone investigation to
search for BM. Taken together, these data should help the
clinician schedule follow-up examination.
2.1. 99mTechnetium ( 99mTc) Bone Scintigraphy. Today, stan-
dard diagnostic algorithms of bone metastases still rely
primarily on 99mTc methylene diphosphonate (MDP) bone
scintigraphy (BS). BS has been used for decades as the first-
line modality for the screening of PCa bone metastases
[22, 23]. 99mTc-MDP is a nonspecific marker of osteoblastic
activity. Studies using microautoradiography have demon-
strated that 99mTc-MDP localizes along mineralization
fronts. The isotope is occasionally found in the substance
of the osteoid but is absent from the cytoplasm and nuclei
of osteoblasts and osteocytes [24]. 99mTc-MDP accumulates
in response not only to tumour but also to degenerative
joint disease, benign fractures, and inflammation [25–27].
Therefore, BS detects bonemetastases at an advanced stage of
tumour infiltration, when osteoblastic reaction to metastatic
cell deposit has occurred [28]. Sensitivities reported in the
literature range between 62 and 89% and, therefore, could
be considered acceptable [28]. BS’s main problem is its
low specificity so that its diagnostic eﬀectiveness has been
widely questioned in the literature [29, 30]. Indeed, in many
cases, regions of increased uptake cannot be definitively
characterized negative or positive for malignancy. Routinely,
it will end up in reading characterized as “equivocal,”
“possible,” “suspicious,” “likely,” “highly suspicious,” “almost
certain,” a series of definition encompassing all cases in
which imaging findings could not be categorized confidently
as metastatic or benign, regardless of the level of incer-
titude. Usually equivocal BS uptakes will be characterized
by targeted X-ray to distinguish benign (fracture, Paget’s,
degenerative joint disease, etc.) from malignant (metastatic)
origin [31]. This association is imperfect, and the diagnosis
may remain equivocal after this workup. In clinical practice,
a normal bone radiograph associated with an abnormal
scan is highly suggestive of BM [32]. But this conclusion
invokes conventional wisdom or suggestion more than it
relies on a robust approach. Conventional wisdom may be
acceptable in clinical practice to assess a fractures risk; it
becomes questionable when it comes to definitive decisions
in oncology [33].
2.2. SPECT and SPECT CT. Noteworthy, guidelines do not
provide technical recommendations for BS. In many centres
BS is limited to anterior and posterior planar images. Stan-
dard planar BS can be improved by single-photon emission
computerized tomography (SPECT) on selected areas such
as the lower thoracic and lumbar spine region or even on
the entire axial skeleton (Whole-body SPECT) [33–35]. In
cancer patients in general and in PCa in particular, SPECT
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enhances both sensitivity and specificity for the detection of
BM [34–36]. Even-Sapir et al. have compared BM detection
by BS, SPECT, 18F-Fluoride PET, and 18F-Fluoride PET/CT
in 44 patients with high-risk PCa, including 23 (52%)
with BM [36]. The sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) of planar
BS were 70%, 57%, 64%, and 55%, respectively, and of
SPECT were 92%, 82%, 86%, and 90%, respectively. SPECT
identified 62% of the lesions overlooked by planar BS. The
major advantage of SPECT is that the added benefit of
tomographic imaging required few extra radiation dose and
only slight added cost, since most modern cameras now oﬀer
the possibility of whole-body SPECT [33]. Nozaki et al. have
assessed the value of SPECT in the detection of PCa BM
in the lumbar vertebrae in 39 patients, all of them having
increased 99mTc uptake on BS [37]. Definitive diagnosis of
BM was established by MRI. Sensitivity, specificity, PPV, and
NPV of bone SPECT were 95.9%, 73.1%, 72.3%, and 96.1%,
respectively. Helyar et al. have investigated the additional
value of SPECT/CT over Tc-99m BS and SPECT on 50
lesions detected by BS in 40 patients [38]. On reporting
the planar study and SPECT scans, reviewers rated 61% of
lesions as equivocal. On reporting the SPECT/CT scans, only
8% of lesions were rated as equivocal, 24% were rated as
malignant, and 68% as benign.
As a conclusion, SPECT and SPECT/CT provide better
accuracy than Tc99m BS in diﬀerential diagnosis of lumbar
BM. Because whole-body SPECT is time-consuming and not
widely available, it is not yet recognized as the “optimal state-
of-the art” screening technique, although it is available on
most standard BS machine and can be performed at minimal
cost increased.
2.3. Metabolic Imaging, PET, and PET/CT. Tumour detec-
tion, using positron emission tomography (PET) and
PET/CT, has emerged as a standard imaging techniques in
oncology, since PET/CT has demonstrated higher sensitivity
for the early detection of metastases, including BM, in var-
ious malignancies [39–41]. Unfortunately, the most widely
used metabolic marker, 18F-FDG PET, has little or even no
interest in PCa patients. Ghanem et al. have demonstrated
that 18F-FDG-PET alone or using PET-CT image fusion, is
less sensitive than MRI in the detection of bone metastases
[42]. 18F-(Sodium) Fluoride is a high aﬃnity bone-seeking
agent usually considered as a promising substitute for 99mTc-
MDP. In the aforementioned series of 44 high-risk PCa,
Even-Sapir et al. has reported sensitivity, specificity, PPV,
and NPV of, respectively, 100%, 62%, 74%, and 100% for
18F-Fluoride PET and of 100% for all parameters for 18F-
Fluoride PET/CT [36]. Of the 156 bone lesions detected
by 18F-Fluoride, 81 lesions (52%), including 34 metastases,
were overlooked with normal appearance on planar BS. In
contrast, the other aforementioned trial by Ghanem et al.
failed to show superiority of 18F-Fluoride PET over MRI in
BM detection [42].
Future studies will focus on newer markers such as
11C- or 18F-labeled choline and acetate, 11C-methionine,
and 18F-fluorodihydrotestosterone [26, 36, 40–44]. Kotzerke
et al. have compared 11C-acetate and 11C-choline uptake
in 12 PCa patients and concluded that the ability of both
radiotracers to detect known BM was identical, although
interindividual variation was high [45]. Yu et al. have tested
the feasibility of 11C-acetate and 18F-FDG for the detection
and measurement of response to therapy in 8 patients
detected with ≥3 BM diagnosed by 99mTc BS. 11C-acetate
PET detected BM in all 8 patients, whereas 18F-FDG PET
detected lesions in 6 of the 7 imaged patients [46]. Beheshti
et al. have prospectively compared the potential value of 18F-
fluorocholine and 18F-fluoride PET/CT for BM detection
in 38 PCa patients [47]. In case of discrepant results,
follow-up was used as validator. Overall, 321 lesions were
evaluated in this study. Sixteenmalignant osteoblastic lesions
were negative with both 18F-fluorocholine and 18F-fluoride
PET/CT. The sensitivity, specificity, and accuracy of PET/CT
for PCa BM detection was 81%, 93%, and 86% for 18F-
fluoride and 74% (P = 0.12), 99% (P = 0.01), and 85% for
18F-fluorocholine PET/CT, respectively. In a later study on 70
patients, Beheshti et al. have calculated that the sensitivity,
specificity, and accuracy of 18F-fluorcholine PET/CT in
detecting PCa BMwas 79%, 97%, and 84%, respectively [48].
Eschmann et al. have published a small study on 42 patients
aiming to compare the diagnostic accuracy of 11C-Choline
PET/CT and whole-body WB-MRI [49]. After validation by
histology, follow-up, or consensus reading, 88/103 detected
lesions were considered as malignant including 44 BMs.
Sensitivity, specificity, and accuracy for 11C-choline PET/CT
were 96.6%, 76.5%, and 93.3%, respectively, and for WB-
MRI 78.4%, 94.1%, and 81.0%, respectively. Interestingly,
however; whole-body MRI was performed without diﬀusion
reading, thus, lowering its performance.
3. CT Scanner
CT scanner imaging is central in the diagnosis of muscu-
loskeletal disorders. In bone malignancies, it is not used
as a screening test but as a second-line imaging technique
to clear-up abnormal BS uptakes remaining unexplained
after standard X-ray or to image suspicion of neurological
disorders.
Recently, the development of multidetector spiral tech-
nology has reawakened the potential interest of CT for early
detection of BMs. In a recent analysis, Groves et al. have
investigated the value of this technique in BM assessment
[50]. They have compared BS and bone imaging from the
cranium vertex to the knee by 16-slices CT in 43 patients with
knownmalignancy. BS detected BM in 14/43 andCT in 13/43
patients. There were, however, several discordances. Based on
their preliminary analysis, Groves et al. concluded that CT
with its present performance is unlikely to replace BS for BM
screening. In addition, the total accumulated radiation dose
required by whole spine CT precludes the systematic use of
this technique for the determination of therapeutic response
in clinical trials.
4. Magnetic Resonance Imaging (MRI) of
the Skeleton
MRI is highly sensitive for detecting BM in cancer patients
[25, 31, 51–53]. Its superiority over BS has been repeatedly
demonstrated [54–56]. It has been used as a “gold standard”
to evaluate PET for detecting BM and more recently to
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quantify PCa metastases and measure tumour response to
therapy [30, 57]. However, the use of MRI in first line is
often presented as “not feasible” putting forward its limited
availability, costs, or limitations of published series validating
the method [30].
MRI characteristics of malignant involvement of the
bone marrow are well documented [25, 36, 57–59]. The
diﬀerent MRI patterns of bone marrow involvement in neo-
plastic disease have been precisely described, so that discrim-
inatingmetastatic lesions from benignmarrow abnormalities
such as marrow hyperplasia induced by chemotherapy can
easily be made by trained radiologists. MRI appearance
of the spinal and pelvi-femoral can be categorized into
simple well-defined categories [58, 60]: normal appearance,
focal metastatic lesions (focal marrow replacement pattern),
which are nodular areas that can be measured, and diﬀuse
marrow infiltration (Figure 1).
The superiority of MRI lies in its ability to detect early
tumour cells seeding into the hematopoietic compartment,
leading to replacement of the normal hematopoietic marrow
and of its fat cells. This technique, thus, identifies BM at an
early stage, before host reaction of the osteoblasts becomes
visible on BS and X-ray, therefore, increasing sensitivity
[25, 28]. Already in 1993, Turner et al. reported on using
MRI in 18 PCa patients to resolve conflicting evidence of
BM found on bone scans and X-ray [61]. MRI ruled out
metastatic disease in 2 of the 8 positive BS and revealed
BM in 5 negative BS. All 5 equivocal BS demonstrated
no osseous lesions on MRI. In addition, in 6 patients
with evidence of BM serial MRI scans following ADT
demonstrated radiographic and clinical improvement. In
2000,Walker et al. evaluated whole-body STIR-MRI to detect
metastases to liver, brain, and bone as a single examination
in women with breast cancer [62]. BM were identified in
11/17 patients, with correlation between findings at whole-
body MRI and scintigraphy in 15/17 patients. Daldrup-Link
et al. have compared the diagnostic accuracy of whole-body
MRI, Tc-99m BS, and FDG-PET for the detection of bone
metastases in 39 children aged 2 to 19 years old with various
malignancies [28]. Sensitivities for the detection of bone
metastases were 90% for FDG-PET, 82% for MRI, and 71%
for skeletal scintigraphy. But FDG-PET also produced most
false-positive lesions. More recently, our group has evaluated
the diagnostic performance and impact on therapy of one-
step MRI of the axial skeleton (MRIas) for detecting BM
in 66 patients with high-risk PCa [63]. MRIas has been
compared to a routine workup based on BS completed with
targeted X-ray in cases of equivocal BS findings and with
MRI “on request” (MRIor) in case of inconclusive BS/X-
ray findings. Sensitivities were 46% for Tc-99m BS alone,
63% for BS/X-ray, 83% for BS/X-rays/MRI, and 100% for
MRIas. Corresponding specificities were 32%, 64%, 100%,
and 88%. MRIas was significantly more sensitive than any
other approach (P < 0.05, McNemar). MRIas correctly
identified metastases in 7/23 (30%) patients considered
negative, and 8/17 (47%) considered equivocal by other
strategies, which resulted in altering the initially planned
therapy. This increased sensitivity has clearly an added value
in routine practice, both in newly diagnosed PCa, to avoid
unnecessary radical therapy, and later on in the disease to
enable early initiation of treatment with the hope to prevent
or delay the complications of metastases.
Are these results suﬃcient to definitively state that MRI
will replace BS as initial and sole imaging modality for
staging all PCa patients? The answer is no. The access to MRI
technology still needs to be improved and the available MRI
machine to be increased. Indeed, it is not often acceptable to
delay treatment in high-risk patients waiting to rule out BM.
In addition, many authors still advocate the use of BS on the
assumption that MRI would be too costy [25, 26, 39]. These
data, however, demonstrate that MRI surpasses the current
imaging strategy used for bone staging in a high-risk patient
population. There is place for large multicentric studies in
well-defined groups of patients to assess and confirm the
clinical eﬃcacy of MRI as the initial tool for bone staging in
PCa.
Further development will focus on whole-body MRI
(WBMRI). Hardware and software advances have enabled
the acquisition of WBMRI, including conventional sequence
(T1, STIR) images covering the entire skeleton, and more
recently diﬀusion-weighted images (DWIs), which facilitates
the detection of BM, especially in skeletal areas that are
diﬃcult to evaluate on conventional sequences, such as
ribs [64–68]. In addition, this allows envisioning an all-in-
one metastatic workup (visceral and osseous). Eschmann et
al. have compared the diagnostic accuracy of 11C-Choline
PET/CT to whole-body MRI for the staging workup of PCa
in 42 patients [44]. Sensitivity, specificity, and accuracy for
11C-Choline PET/CT were 96.6%, 76.5%, and 93.3%, respec-
tively, and for MRI 78.4%, 94.1%, and 81.0%. Interestingly,
3 BMs had initially been missed by 11C-Choline PET/CT
and were found retrospectively. The author concluded
that strength of MRI is excellent image quality providing
detailed anatomical information whereas the advantage of
Choline PET/CT is high image contrast of pathological foci
(Figure 2).
5. Conclusion
Correct diagnosis of BM has emerged as major challenge
for those who are developing new therapeutic strategies,
including those who advocate aggressive local treatment of
high-risk localized and locally advanced disease. Tc-99m
BS may not be over, but the time when patients would
be treated on suspicion rather than on robust evidences is
passed. Many technologies including metabolic imaging by
PET and MRI are indeed rapidly gaining interest in the
everyday management of PCa patients. As it is for modern
treatments, the diagnosis strategies will be multidisciplinary
by nature and involve crossfertilization between nuclearists,
urologists, and radiation oncologists.
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